Here are Friday's biggest analyst calls: Nvidia, SpaceX, Tesla, Apple, Mobileye, EchoStar, Toll Brothers & more

Wall Street research calls were broadly positive, with multiple upgrades and new Buy or Outperform initiations, including Goldman Sachs raising Fox to Buy and lifting its price target to $85 from $54. Analysts cited potential earnings growth, business turnarounds and AI-related opportunities; Evercore raised its SpaceX target to $275 from $230, while UBS reiterated Apple at Neutral based on roughly four-day shorter year-over-year iPhone Pro wait times. These are analyst opinions and forecasts, not reported company results.

Analysis

Treat this roundup as a map of changing narratives, not a basket of fresh fundamental signals: most items are initiations or rating changes, and the supplied information does not establish earnings revisions or valuation support. The most consequential debate is whether AI spending remains durable. If NVIDIA’s channel checks translate into sustained orders and timely Blackwell shipments, the recent concern set could unwind; the counter-risk is that demand shifts toward more inference-efficient architectures or shipment timing slips. The near-term test is NVIDIA’s guidance and delivery cadence, not broker conviction alone.

Tesla’s energy-and-compute framing is a potential multiple narrative shift, but only if upcoming disclosure shows repeatable deployments and economics large enough to matter alongside autos. Until then, it is an earnings-call diligence item, not a reason to capitalize a new business at scale. FOX’s pending Roku transaction could widen distribution and ad-sales options, while also adding integration and strategic-execution risk; the key is whether pro forma guidance demonstrates measurable monetization rather than simply a broader platform story.

The biotech valuations for Praxis Precision Medicines and Revolution Medicines are especially sensitive to clinical and regulatory milestones; price targets do not resolve binary trial risk. Likewise, Zeta’s positive call after a strong run may attract momentum, but the setup depends on reported growth converting into cash generation. The broad mildly positive tone risks making crowded upgrades look like catalysts. Over 6–18 months, evidence of earnings conversion matters more than the rating changes; a guidance miss, delayed product delivery, or adverse clinical/regulatory outcome would reverse the relevant theses.

Key Decisions for Investors

• Prefer a conditional long NVIDIA over a broad AI basket only if earnings guidance and shipment commentary confirm demand and Blackwell delivery; reduce or exit on a material guidance cut or renewed delivery slippage. Do not treat broker channel checks as proof.
• Keep Tesla on an event watchlist rather than adding ahead of earnings. Look for reported energy deployment, segment economics, and evidence that the business is material to consolidated results; absent that evidence, do not pay for the compute-and-power narrative.
• Avoid chasing Zeta Global on the analyst upgrade alone. Revisit after results for growth-to-cash conversion and guidance follow-through; weakening reported growth or cash generation would falsify the bullish setup.
• For FOX, monitor transaction terms, closing conditions, and the first pro forma operating guidance before trading the acquisition thesis. If integration costs or monetization evidence disappoint, the strategic-premium case is impaired; the article provides insufficient detail for a merger-spread trade.
• Treat PRAX and RVMD as milestone-driven, high-binary-risk exposures rather than valuation-target trades. Verify upcoming clinical/regulatory catalysts and financing runway before sizing; no clinical data or catalyst calendar is provided here.